Page last updated: 2024-10-31

mirtazapine and Drug Hypersensitivity

mirtazapine has been researched along with Drug Hypersensitivity in 2 studies

Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Anghelescu, I1
Klawe, C1
Dahmen, N1
Brown, MC1
Nimmerrichter, AA1
Guest, JF1

Reviews

1 review available for mirtazapine and Drug Hypersensitivity

ArticleYear
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
    European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:4

    Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria;

1999

Trials

1 trial available for mirtazapine and Drug Hypersensitivity

ArticleYear
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
    European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:4

    Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria;

1999

Other Studies

1 other study available for mirtazapine and Drug Hypersensitivity

ArticleYear
Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9

    Topics: Agranulocytosis; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Comorbi

2002